Literature DB >> 16786118

Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?

Eugene T H Ek1, Joseline Ojaimi, Yasuyuki Kitagawa, Peter F M Choong.   

Abstract

The role of angiogenesis as a prognostic indicator in cancer has been extensively studied in recent times with several studies demonstrating a positive correlation for various malignant tumours. However, the role of angiogenesis in osteosarcoma remains a topic of debate. In this study, we aim to evaluate the significance of intratumoural microvessel density (MVD) and the degree of vascular epithelial growth factor (VEGF) expression as markers of angiogenesis and correlate this with disease outcome. Archival paraffin-embedded pre-treatment biopsy tissue of patients treated at St. Vincent's Hospital, Melbourne, with non-metastatic osteosarcoma at initial diagnosis was reviewed. Tissue was processed for immunofluorescent staining of the microvascular endothelial cells with antibodies directed against CD31 and CD34. The degree of angiogenesis was assessed, as determined by the microvessel density (MVD). Further histological examination was performed to assess the degree of VEGF expression. Histological observations were correlated with various clinicopathological factors and patient outcome in terms of recurrence, metastasis and death. Twenty-five cases were reviewed, 15 were male and 10 were female, and the median age was 26 years (range, 13-85). The mean follow-up was 21.5 months (range, 3-75 months). The median MVD was 43 microvessels/0.26 mm2 (range, 25-54) and 46 microvessels/0.26 mm2 (range, 30-58) for CD31 and CD34, respectively. Despite the moderate to high vascularity, there was no significant difference noted between the MVD and disease outcome factors for both CD31 and CD34. There was a trend towards a higher MVD in patients aged > 40 years compared to those < 40 years (p = 0.110 for CD31 and p = 0.097 for CD34). In terms of VEGF expression, 24 of 25 cases demonstrated either moderate or strong expression; however, no prognostic significance was determined. In this study, we were able to demonstrate that osteosarcoma is a relatively vascular tumour; however, the degree of MVD and VEGF expression does not provide prognostic information. It is likely that angiogenesis plays a key role in the pathogenesis of osteosarcoma and is, therefore, a potential target for novel anti-angiogenic therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786118

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

Review 1.  The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.

Authors:  Jin-Tao Qu; Mei Wang; Hai-Long He; Yu Tang; Xiao-Jian Ye
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-25       Impact factor: 4.553

2.  Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.

Authors:  Jilong Yang; Da Yang; Yan Sun; Baocun Sun; Guowen Wang; Jonathan C Trent; Dejka M Araujo; Kexin Chen; Wei Zhang
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

3.  Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma.

Authors:  Pengfei Lei; Dengfeng Ding; Jie Xie; Long Wang; Qiande Liao; Yihe Hu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

4.  Vascular patterning in human heterotopic ossification.

Authors:  Margaret Cocks; Aditya Mohan; Carolyn A Meyers; Catherine Ding; Benjamin Levi; Edward McCarthy; Aaron W James
Journal:  Hum Pathol       Date:  2017-03-14       Impact factor: 3.466

5.  Comment on Xu XW et al.: Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.

Authors:  Shaozhong He; Zhenyu Xiao; Longhua Chen; Shizhong Xiong
Journal:  Tumour Biol       Date:  2014-05-23

6.  Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.

Authors:  Xiao-Wei Yu; Tian-Yi Wu; Xiang Yi; Wei-Ping Ren; Zu-bin Zhou; Yu-qiang Sun; Chang-qing Zhang
Journal:  Tumour Biol       Date:  2013-08-02

Review 7.  A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma.

Authors:  Ding Chen; Ye-Jia Zhang; Ke-wei Zhu; Wan-Chun Wang
Journal:  Tumour Biol       Date:  2013-04-16

Review 8.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

9.  Possible prognostic role of IL-17R in osteosarcoma.

Authors:  Maria Cristina Honorati; Luca Cattini; Andrea Facchini
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-10       Impact factor: 4.553

10.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.